JP2006516571A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516571A5
JP2006516571A5 JP2006500981A JP2006500981A JP2006516571A5 JP 2006516571 A5 JP2006516571 A5 JP 2006516571A5 JP 2006500981 A JP2006500981 A JP 2006500981A JP 2006500981 A JP2006500981 A JP 2006500981A JP 2006516571 A5 JP2006516571 A5 JP 2006516571A5
Authority
JP
Japan
Prior art keywords
composition
lonidamine
bph
benign prostatic
prostatic hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516571A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/001141 external-priority patent/WO2004064735A2/en
Publication of JP2006516571A publication Critical patent/JP2006516571A/ja
Publication of JP2006516571A5 publication Critical patent/JP2006516571A5/ja
Pending legal-status Critical Current

Links

JP2006500981A 2003-01-17 2004-01-16 良性前立腺増殖症の処置 Pending JP2006516571A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US44111003P 2003-01-17 2003-01-17
US44234403P 2003-01-23 2003-01-23
US45884603P 2003-03-28 2003-03-28
US45866503P 2003-03-28 2003-03-28
US45866303P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US47290703P 2003-05-22 2003-05-22
US48826503P 2003-07-18 2003-07-18
US49616303P 2003-08-18 2003-08-18
PCT/US2004/001141 WO2004064735A2 (en) 2003-01-17 2004-01-16 Treatment of benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
JP2006516571A JP2006516571A (ja) 2006-07-06
JP2006516571A5 true JP2006516571A5 (enExample) 2007-03-01

Family

ID=32777423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006500981A Pending JP2006516571A (ja) 2003-01-17 2004-01-16 良性前立腺増殖症の処置
JP2006500983A Withdrawn JP2006518343A (ja) 2003-01-17 2004-01-16 エネルギー減損因子を用いた良性前立腺増殖症の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006500983A Withdrawn JP2006518343A (ja) 2003-01-17 2004-01-16 エネルギー減損因子を用いた良性前立腺増殖症の処置

Country Status (13)

Country Link
US (4) US6989400B2 (enExample)
EP (2) EP1610778A4 (enExample)
JP (2) JP2006516571A (enExample)
KR (2) KR20050098249A (enExample)
AU (2) AU2004206870A1 (enExample)
BR (1) BRPI0406796A (enExample)
CA (2) CA2513575A1 (enExample)
DE (1) DE04702967T1 (enExample)
ES (1) ES2254046T1 (enExample)
IL (1) IL169685A0 (enExample)
MX (2) MXPA05007572A (enExample)
NO (1) NO20053783L (enExample)
WO (2) WO2004064735A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US7524885B2 (en) * 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
EP1610778A4 (en) 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
AU2005258021B2 (en) 2004-06-17 2008-12-18 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure and paroxysmal disorders
WO2006091790A1 (en) 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
WO2007101148A2 (en) * 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
CA2694216A1 (en) 2007-07-24 2009-01-29 Astellas Pharma Inc. Benzimidazole derivative
HRP20120837T1 (hr) 2007-08-31 2012-11-30 Astellas Pharma Inc. Derivati piperidina
US8603123B2 (en) * 2008-04-28 2013-12-10 Urotech, Inc. Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration
PL2331092T3 (pl) * 2008-08-21 2014-08-29 Univ Johns Hopkins Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
JP6068803B2 (ja) * 2009-01-29 2017-01-25 コー，ヤング，ヒー 癌治療用組成物及び癌治療方法
WO2013153821A1 (ja) * 2012-04-12 2013-10-17 Omura Satoshi Ｐｄｋ４阻害剤及びその利用
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
CN106102725A (zh) 2014-01-14 2016-11-09 约翰斯·霍普金斯大学 包封选择性atp抑制剂的环糊精组合物及其应用
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
CN116438162A (zh) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US4684627A (en) 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
FR2737721B1 (fr) 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
DE69521525T2 (de) 1995-10-18 2002-04-25 Kanoldt Arzneimittel Gmbh Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
DE19621319A1 (de) 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
IT1289939B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用
AU3980499A (en) * 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6001865A (en) * 1999-05-04 1999-12-14 Angelini Pharmaceuticals Inc. 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents
EP1610778A4 (en) 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
CN1960719B (zh) * 2004-03-25 2011-12-07 密执安州立大学董事会 棉酚共结晶及其应用

Similar Documents

Publication Publication Date Title
JP2006516571A5 (enExample)
JP6527497B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
JP2005506367A5 (enExample)
JP2007536311A5 (enExample)
CN109640981A (zh) 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
BR0009016A (pt) Composição de apomorfina e sildenafil
JP2005508840A5 (enExample)
JP2001510795A5 (enExample)
JP2002527401A5 (enExample)
JP2009501801A5 (enExample)
ES2254046T1 (es) Tratamiento de hiperplasia prostatica benigna.
JP2002528502A5 (enExample)
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2006513184A5 (enExample)
JP2005508338A5 (enExample)
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
JP2004537500A5 (enExample)
JP2020500864A5 (enExample)
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2007138867A (ru) Режимы дозирования транс-кломифена
JP2007501806A5 (enExample)
CA2721728A1 (en) Treatment of inflammatory bowel disease with 6-mercaptopurine
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов